Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;38(2):527-33.
doi: 10.1007/s10753-014-9959-1.

Protective effects of embelin on myocardial ischemia-reperfusion injury following cardiac arrest in a rabbit model

Affiliations

Protective effects of embelin on myocardial ischemia-reperfusion injury following cardiac arrest in a rabbit model

Zhi-Gang Zhao et al. Inflammation. 2015 Apr.

Abstract

Embelin has been used to treat fever and inflammatory diseases for thousands of years. Although reports indicate that embelin has antiinflammatory effects, its effects on myocardial injury following cardiac arrest (CA) have not been previously explored. In this study, we aim to investigate the protective effects of embelin on myocardial ischemia-reperfusion injury (IRI) following CA in a rabbit model. Pro-inflammatory (TNF-α, IL-1β, and IL-6) cytokines, cardiac troponin I (cTnI), necrosis ratio, apoptotic index (AI), hemodynamics, nuclear factor-kappa B (NF-κB) p65, and histological damage have been measured or evaluated. Embelin reverts TNF-α, IL-1β, and IL-6 to basal levels and reduces the serum level of cTnI, the necrosis ratio, the AI, and the expression of NF-κB p65. Meanwhile, it improves the hemodynamics and myocardial function. Moreover, embelin-treated groups also showed improved myocardial morphology. Our results indicate that embelin may protect the heart against myocardial IRI following CA via its antiinflammatory abilities.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Mol Pharmacol. 2007 Jan;71(1):209-19 - PubMed
    1. Eur J Pharmacol. 2011 Mar 1;654(1):100-5 - PubMed
    1. PLoS One. 2014 Apr 22;9(4):e95846 - PubMed
    1. J Pharmacol Sci. 2013;121(3):192-9 - PubMed
    1. Inflammation. 2013 Apr;36(2):468-75 - PubMed

MeSH terms

LinkOut - more resources